{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=22", "query": { "intervention": "Progressive", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 2386, "total_pages": 239, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T19:34:30.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004036", "title": "Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004036" }, { "nct_id": "NCT03637998", "title": "Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Low Back Pain", "Self-Management" ], "interventions": [ { "name": "Problem-solving Pain to Enhance Living Well (PROPEL)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Connecticut", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2018-09-21", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 1, "location_summary": "Storrs, Connecticut", "locations": [ { "city": "Storrs", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637998" }, { "nct_id": "NCT05117008", "title": "Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Relapse Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-07-19", "completion_date": "2024-01-15", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05117008" }, { "nct_id": "NCT02625610", "title": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2015-12-24", "completion_date": "2021-06-03", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 35, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625610" }, { "nct_id": "NCT07033481", "title": "Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonfluent Variant Primary Progressive Aphasia (nfvPPA)" ], "interventions": [ { "name": "Neflamapimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EIP Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 20, "start_date": "2025-10-02", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 5, "location_summary": "Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07033481" }, { "nct_id": "NCT00025363", "title": "Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alveolar Childhood Rhabdomyosarcoma", "Embryonal Childhood Rhabdomyosarcoma", "Embryonal-botryoid Childhood Rhabdomyosarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Rhabdomyosarcoma" ], "interventions": [ { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 150, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025363" }, { "nct_id": "NCT07242963", "title": "Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Medulloblastoma Recurrent", "Medulloblastoma, Childhood, Recurrent", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype" ], "interventions": [], "intervention_types": [], "sponsor": "Mohammad H. Abu Arja", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "3 Years to 50 Years" }, "enrollment_count": 300, "start_date": "2025-09-30", "completion_date": "2035-12-30", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07242963" }, { "nct_id": "NCT03746535", "title": "Cardiovascular Disease Risk in Women With Endometriosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 21, "start_date": "2022-07-01", "completion_date": "2025-05-27", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746535" }, { "nct_id": "NCT06870968", "title": "FIT-ATOMIC Exercise Feasibility Trial", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neuroinflammatory Diseases", "Multiple Sclerosis" ], "interventions": [ { "name": "Exercise Training", "type": "BEHAVIORAL" }, { "name": "Mobility and Flexibility Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "The Hospital for Sick Children", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "11 Years to 25 Years" }, "enrollment_count": 40, "start_date": "2025-06", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 2, "location_summary": "La Jolla, California • Philadelphia, Pennsylvania", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06870968" }, { "nct_id": "NCT06013579", "title": "Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Cognitive Impairment" ], "interventions": [ { "name": "Phase 1 Gym Exercise HIIT", "type": "BEHAVIORAL" }, { "name": "Phase 1 Gym Exercise CME", "type": "BEHAVIORAL" }, { "name": "Phase 2 Home Exercise Coaching Text Messages", "type": "BEHAVIORAL" }, { "name": "Phase 2 Home Exercise Control Text Messages", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 110, "start_date": "2023-08-01", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-24T19:34:30.602Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013579" } ] }